Talk:Sophia Genetics
 | This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||
Awards
The awards section needs immediate clean-up. Any award that is primary sourced –e.g. cited to the awarding media outlet – is liable to be deleted. ☆ Bri (talk) 18:10, 17 June 2020 (UTC)
- Deleted section. The other problem was that most if not all of these awards were lists of 50 or 100 awardees, which makes them even less appropriate for an encyclopedia. One award was also to the CEO as an individual, not to the company. All in all, this falls under PR style writing as documented at WP:Identifying PR. ☆ Bri (talk) 01:13, 18 June 2020 (UTC)
History edit request
Hello Wikipedia editors, I'm Kelly, and I'm here on this Talk page as a Sophia Genetics employee to post my first edit request. I understand the importance of declaring a conflict of interest as an employee of the company, so I posted a detailed explanation of my COI on my user page here: User:Comms Kelly.
For this update, I've put together the most significant change I'm proposing: to absorb the Funding section of the article into the History section, keeping only the most essential bits of information. I totally understand why there is a Funding section within the article now, but since the company went public in 2021, offering a detailed breakdown of every minor round of funding from the 2010s seems like an over-explanation of now irrelevant information. Below, I'll list all the changes I'm proposing:
- Updated the description of the Sophia DDM platform in the second paragraph of the History section, citing the following outlets to verify updated information: FierceBIotech, Medical Device Network, and TechCrunch. Also, I removed the TechTour citation from the section as the link is broken. Overall, I attempted to simplify the explanation of what the DDM platform does.
- Removed the final sentence from the section's third paragraph, which read, "The algorithms were built bottom-up from raw FASTQ data." This read as way too science-specific for Wikipedia.
- Removed the Funding section and ported over the funding round of Series E, Series F, and the paragraph about the company going public to the History section. I kept Series E because many high-quality citations were attached to this fundraising round.
- Removed the following rounds of funding: Series A, Series B, Series C, and Series D.
- In the paragraph regarding the acquisition of Interactive Biosoftware, added that IB was acquired for Alamut and added a small explanation of the product. I removed previous citations for this sentence (ICT Journal and La Tribune). I replaced them with citations from MobiHealthNews and GenomeWeb, which are better sources on the deal's specifics.
- Removed the mention of Lara Hashimoto becoming Sophia's CBO because the citation link to her appointment at the company was broken. I attempted to find a replacement source but could not find anything of high quality also, coupled with the fact that she has since left the company, it made sense to remove it.
- Removed the sentence about Sophia supporting 100 university hospitals in the US. I'll defer to editors, of course, but it did seem unbalanced to add just this one specific number.
- Added the phrase "in response to the COVID-19 pandemic" in the sentence regarding Sophia's data analysis solution that was focused on predicting the disease evolution of the SARS-CoV-2 virus.
- I removed the mention of Sophia Genetics being listed on the Nasdaq towards the end of the article since this has already been addressed in an earlier section of the article.
- Added a sentence about how there are 780 healthcare organizations within the Sophia DDM Network, cited to GEN.
- Added a sentence about how, in 2022, Sophia Genetics hit one million genomic profiles, cited to Inside Precision Medicine.
- Updated all access dates within each citation to show editors that each has been reviewed in this proposed update. I went through each of them and they all seem to be working and valuable.
Here is a drop-down box with the new History draft:
History draft
|
|---|
HistorySophia Genetics was co-founded by Jurgi Camblong, Pierre Hutter, and Lars Steinmetz in 2011 as a start-up at École Polytechnique Fédérale de Lausanne (EPFL).[1] It began as a research tool for hospitals and federally regulated health care labs, and then expanded to biopharma institutions.[1] In 2014, the company introduced the analytical software platform Sophia DDM (Data-Driven Medicine),[2] a cloud-based software-as-a-service platform that uses machine learning and AI algorithms to provide genomic insights to doctors and researchers from complex multimodal datasets.[3][4][5] Insights are shared across the platform's network, so as the user base scales, the AI becomes more accurate.[3][5] The platform is used for oncology and rare disease research.[5] The company initially designed the platform to help hospitals with processing and storing large genomic data-sets, but research showed that the more pressing problem was data accuracy.[5] That then became the platform's primary focus. The startup worked with hospitals to benchmark DNA samples analyzed via their sequencing systems, and then trained algorithms of their own to perform the diagnosing process automatically and recognize relevant patterns in the genome data.[5] To use the platform, DNA is extracted from a patient sample, enriched, and sequenced by an NGS machine.[5] Once this data has been digitized, it is loaded into the platform. The SOPHiA DDM Platform's AI algorithms then pull out unique genetic variants and pre-classifies data according to pathogenic predictions.[5] Doctors and researchers can then review the detected variants and take action – the SOPHiA DDM Platform in turn learns from those actions[5] In 2017, Sophia Genetics was ranked as one of the 50 smartest companies in the world by the MIT Tech Review.[6] In 2018, the company opened its first research and development center in France and acquired and genetic analytics software development company, Interactive Biosoftware, and Alamut, the company's clinical decision support software.[7][8] That same year, Sophia Genetics opened its U.S. headquarters in Boston, Massachusetts.[9] The company also received the Salus Partner Excellence in HealthTech Award in 2018.[10] Sophia Genetics raised multiple rounds of funding before going public, including $77 million in January 2019 as part of a Series E round of funding, led by Generation Investment Management.[11][12][13] In 2020, the company appointed Troy Cox, a former board of directors member, as its new chairman.[14] In August, in response to the COVID-19 pandemic, the company released a data analysis solution that was focused on predicting the disease evolution of the SARS-CoV-2 virus.[15] The platform’s AI system was designed to conduct a full-genome analysis of the virus. It then combines that data with patient genetic information, and clinical data such as the results of lung and CT scans to discover abnormalities predictive of disease evolution.[15] Sophia Genetics also received the Best Overall Genomics Company in the 2020 MedTech Breakthrough Awards.[16] In October 2020, as part of a Series F round of funding, the company raised $110 million led by aMoon, a health-tech and life sciences venture fund based in Israel, and Hitachi Ventures, a venture arm of Japanese Hitachi Group.[17] In 2021, Sophia Genetics went public, trading under the symbol SOPH on the Nasdaq.[18][19] The company raised $234 million in its IPO and was backed by J.P. Morgan, Morgan Stanley, Cowen, and Credit Suisse.[19] Later in 2021, the company was named a Microsoft Partner of the Year finalist.[20] At the time, its platform was in use at more than 750 hospitals, laboratories, and biopharma institutions around the world and had analyzed over 770,000 genomic profiles worldwide.[3][4] As of 2021, the company had 780 healthcare organizations within the Sophia DDM network.[21] In April 2022, Sophia Genetics had analyzed over 1,000,000 genomic profiles.[22] Later in 2022, Sophia Genetics was named one of the 100 Best Places to Work in Boston by Built in Boston.[23] Also in 2022, the firm began development of a new method for detecting extrachromosomal DNA through collaboration with startup firm Boundless Bio.[24] References
|
I understand that this is a reasonably large edit request and that there will likely be feedback from editors. I'm certainly prepared to work together to get this draft to the best place possible within Wikipedia's guidelines. Thank you so much for taking the time to evaluate this draft, and I'll be around for responses as they come. Comms Kelly (talk) 21:04, 2 December 2024 (UTC)
Note re: COI edit request above
For some reason I am unable to respond directly within the thread above, so I am starting a new thread to allow me to do so. Much of the present article is of a highly promotional nature, which is unsurprising given that 75% of the text was added by single purpose accounts which must surely have been associated with the company in some way. Really this article needs to be dramatically stripped back before new material is added. (Copying in user:Comms Kelly.) Axad12 (talk) 08:05, 5 December 2024 (UTC)
- Following on from my note above, I have now removed a significant amount of material from the article. This mainly consisted of promotional material, material in relation to funding, material in relation to awards, and material where company products were described in detail.
- I would suggest that you go back to the drawing board with the COI edit request above. It would be best to start a new request thread below, using the revised article as a base, and not adding any material of the type now removed. It would also be useful if the requested additions were clearly marked so as to allow volunteers to see at a glance what is being requested to be added.
- Hopefully the above notes are of assistance.
- Kind regards, Axad12 (talk) 08:21, 5 December 2024 (UTC)
- Hello User:Axad12, thank you for your attention to this page. I understand that there was content in the article that was potentially added by someone connected to the company in the past, and I just wanted to note that since I joined the company fairly recently, I have aimed to make sure that the company follows Wikipedia's guidelines and Terms of Use. My only experience with Wikipedia has been this engagement.
- The edit you made to the page was fair, as much of that content needed to be removed. As far as the flag on the page goes, it seems that you have removed most, if not all, of the content within the article that the undisclosed COI editor added. I understand that the previous version of the article deserved a flag, but now that it's been stripped down to just the essentials, is the flag still needed? Of course, this comes down entirely to your judgment.
- Regarding future requests, I will certainly use this version of the article as the basis for any future proposed updates. There was some valuable information about the company that was caught in the crossfire of removal in your edit, like the IPO and some of the company's technology, which does have the proper sourcing to be re-added to the article.
- I'll make sure to add these in my subsequent edit request. Again, thank you for your attention here. Comms Kelly (talk) 14:25, 9 December 2024 (UTC)
- Thanks for your post above.
- Yes, I've now removed the tag, no problem.
- Thank you for the approach you are pursuing to getting the article in order, much appreciated. Axad12 (talk) 14:54, 9 December 2024 (UTC)
IPO edit request
Hello, this is Kelly from Sophia Genetics. I'm back on this talk page for another edit request. Since the article has gone through some significant overhaul recently, I took a look at the current version of the article. I noticed a handful of essential bits of history are now missing. While overall, the article is now in a better place thanks to the helpful edits by User:Axad12, I believe a handful of these bits of content should make their way back into the article in some capacity, including what I'm proposing below.
I've whipped up a quick draft that seeks to add back the information about Sophia Genetics' IPO in 2021, managed by J.P. Morgan, Morgan Stanley, and Credit Suisse. I've cited two new sources in the short draft: Boston Business Journal and GenomeWeb.
Here's the drop-down box with the proposed sentence, which would ideally be added at the very end of the History section:
IPO sentence
|
|---|
|
In July 2021, Sophia Genetics went public with an IPO backed by J.P. Morgan, Morgan Stanley, and Credit Suisse.[1][2] References
|
Please let me know if there are any questions about this one. Thank you! Comms Kelly (talk) 18:56, 16 December 2024 (UTC)
Done PK650 (talk) 20:04, 17 December 2024 (UTC)
- Thank you so much! Comms Kelly (talk) 14:32, 6 January 2025 (UTC)
Technology Edit Request
Hello Wikipedia editors, I'm Kelly, and I'm here on this Talk page as a Sophia Genetics employee to post an edit request. I understand the importance of declaring a conflict of interest as an employee of the company, so I posted a detailed explanation of my COI on my user page here: User:Comms Kelly.
For this update, I'd like to propose adding a section after the introduction describing the technology of SOPHiA GENETICS, which incorporates a brief overview and history of the technology behind the company's platform but features only the most essential bits of information. Overall, I attempted to simplify the explanation of what the company's technology platform does and believe readers may understand the topic at hand more with this section added in after the introduction.
Here is a drop-down box with the new Technology draft with citations provided throughout:
Technology draft
|
|---|
TechnologyIn 2014, Sophia Genetics introduced an analytical software platform, the Sophia DDM Platform (Data-Driven Medicine).[1] The data analytics platform allows clinicians to improve genomic diagnostics by applying AI to enhance next-generation sequencing methods.[2] The DDM platform is used for oncology, hereditary cancers, metabolic disorders, pediatrics, cardiology, and for rare disease research.[2] The company initially designed the platform to help hospitals process and store large genomic data sets, but after research showed the more important issue with the technology was data accuracy, the platform's focus shifted.[2] In 2018, Sophia Genetics acquired Nénuphar, a technology that uses patient data and algorithms to predict tumor growth.[3][4] References
|
I understand that there will likely be feedback from editors. I'm certainly prepared to work together to get this draft to the best place possible within Wikipedia's guidelines. Thank you so much for taking the time to evaluate this draft, and I'll be around for responses as they come. Comms Kelly (talk) 22:07, 21 February 2025 (UTC)